Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.54, p.471-477, 2007 |
||
Title: Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia | ||
Author: T. ZELEZNIKOVA, L. STEVULOVA, A. KOVARIKOVA, O. BABUSIKOVA | ||
Abstract: Presented study is focused on exact immunophenotypic definition of myeloid precursors and their following stages in
regenerating bone marrow during treatment of ALL/AML for correct interpretation of the immunophenotype results and
proper distinction from minimal residual disease (MRD) by multiparameter flow cytometry.
This study includes bone marrow samples from 36 controls, 27 patients with AML, 39 patients with B-ALL undergoing
therapy who remained in complete remission after treatment and also 30 B-ALL patients one year after the end of therapy.
We observed substantial expansion of immature bone marrow populations in the regenerating bone marrows, which were
identified by expression of CD34 and/or CD117 markers by 4-color flow cytometry. Myeloid precursors were significantly
increased after cessation of induction therapy cycle of B-ALL (1.27±2.04%, p=0.0064) and also AML patients (0.87±0.77%,
p=0.001), but also during follow-up of B-ALL patients (1.42±2.36%, p=0.0001) when compared with non-treated controls
(0.38±0.29%). Some cases where their frequencies achieved up to 12% reflect the massive regeneration of myeloid lineage
in bone marrow after chemotherapy cycles. Especially in these cases accurate interpretation of such a high frequency of
immature myeloid cells as myeloid precursors was very important to exclude incoming relapse or secondary leukemia. The
myeloid precursors represented by CD34+ in regenerating bone marrow expressed CD45 (94.8±5.5%), CD117 (38.3±26.2%),
CD38 (91.4±5.7%), HLA-DR (90.6±7.6%), CD13 (73.0±20.8%) and CD33 (85.2±15.6%), while CD90 (2.7±2.5%), CD133
(10.0±8.2%) and T or B lymphocyte markers were negative. Comparing immunophenotypes with control bone marrows,
only difference in expression of CD33 marker was found (85.2±15.6% versus 63.0±17.4% p=0.024). In addition, according
to expression of these markers three different subsets of myeloid precursor cells were identified in regenerating bone marrow
samples: CD34+ CD117- HLA-DR+, CD34+ CD117+ HLA-DR+ and CD34- CD117+ HLA-DR-/+ without aberrant marker
expression.
In conclusion for the correct discrimination of MRD in acute leukemia it is indispensable to define the range of normality
in myeloid differentiation by extensive studies of bone marrows not only from healthy donors but also from regenerating
bone marrow of patients undergoing therapy. |
||
Keywords: AML; regenerating bone marrow; minimal residual disease; precursors | ||
Year: 2007, Volume: 54, Issue: | Page From: 471, Page To: 477 | |
|
download file |
|